Don't bash the basher. Who cares if he bashes? It is a free country and idiots are perfectly within their rights to fantasize that they understand anything about anything and then spout their mouths off about it.
EXEL has a natural anti-basher property called "going up 10 - 20% per month" and it is sure to take care of this nomad rash just as it got rid of our bushido infestation.
P.S. FYI, I was exclusively short stocks for about 6 months ending March 10th 2009, so I know how these bashers, with the whole world against them, feel... except for the whole 'losing all your money' part.
"It is a free country and idiots are perfectly within their rights to fantasize that they understand anything about anything and then spout their mouths off about it."
What PPS did you say you were looking for next week "Mothra"? $15, $20, $25??
LMAO. Idiot indeed :)
Nomads $8.43 post in this thread is taking the scenic route!
Here is hoping his prediction gets totally lost on the reality highway!
Right now its on a backroad somewhere and there was a dead-end sign when he turned on the road!
Think Nomad missed the sign!
Nomad was actually spot on with his last call. He pegged it at 7.23 about 3-4 days prior to the low of 7.22. Just a solid technical guy rather than basher IMHO.
But technicals can be a bit tricky with pending catalyst. I'm not on board with his call at this time, the catalyst could bring a nice run, I don't think it is all priced in here.
Would you guys please stop beating each other up every time a differing opinion is expressed. Clarity comes from critical analysis of both sides. Don't take it so personally or I will have to tell you to.....................................................bite me.
No institutions sold, no insiders sold, and Nomad is short trader, his other Id is Bushido.
It is his job to create doubt on messageboards to make people sell to gain on his short trades. The probably here is that he is under water and is drowning . He just chose a bad time to be short EXEL. You don't short a Company like EXEL when they are about to present and give giidance on partners and Company strategy.I believe he will crushed crushed .
He could be a short but there is a great likelihood that he is a shill trying to keep the price lower for more highly capitalized buyers, or for himself. Every once in a while he sounds like he wants to buy and I'm sure he and his friends would like to buy before the ASCO cat is out of the bag.
recently raised that chunk, now sitting on @ 128mm in cash, support @ 8.00/sh. I would have to go back and dig, as I don't generally retain information reviewed, but there are other prospects.
The alpha emitter data you steered me to was a bit concerning as DNA has evaluated a conjugated form of herceptin with the thoruim-227 (Algeta's other product aside from Appharadin) alpha emitter successfully, I did note that it appeared (???) to be way too far behind the curve to be a threat to T-DM1 success.
Primary reason for my previous inquiry on the thread "Could its activity be revealing something much more profound?"
<<Yes looked again, and it is definitely 5%.>>
I haven't given them a hard look in a long time, but I'll give you a real superficial gut feeling. The Herceptin conjugate will be a stunning success. IMGN will use that success to raise another dilutive chunk of cash and they will use that cash and the royalty stream to try to develop a proprietary wholly owned drug as good as the Herceptin conjugate. I don't have very much faith in their ability to accomplish that goal.
"I haven't given them a hard look in a long time, but I'll give you a real superficial gut feeling. The Herceptin conjugate will be a stunning success. IMGN will use that success to raise another dilutive chunk of cash and they will use that cash and the royalty stream to try to develop a proprietary wholly owned drug as good as the Herceptin conjugate. I don't have very much faith in their ability to accomplish that goal."
Looks interesting from http://www.immunogen.com/img/T-DM1%20Ph%20II%201st%20line%20ESMO%2010-10%20from%20ESMO%20site.pdf but I passed awhile back due to that 5% royalty arrangement. If phase 3 works out, one would think the conjugate would absorb most of Herceptin market.